Cardiol Therapeutics (CRDL) Return on Capital Employed (2021 - 2026)
Cardiol Therapeutics' (CRDL) quarterly Return on Capital Employed came in at 175.85% in Q1 2026, up 1878.0% YoY from 8.89% in Q1 2025, and up 9.65% on a QoQ basis from 194.64% in Q1 2025.
Cardiol Therapeutics (CRDL) Return on Capital Employed (2021 - 2026) Analysis & Trends
Cardiol Therapeutics (CRDL) has 5 years of Return on Capital Employed data on file, last reported at 175.85% in Q1 2026.
- Quarterly Return on Capital Employed rose 1878.0% year-over-year to 175.85% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 175.85% (up 1878.0% YoY) and the FY2025 annual result came in at 155.56%, down 1043.0% from the prior year.
- Return on Capital Employed improved to 175.85% in Q1 2026, from 194.64% in the prior quarter.
- In the past five years, Return on Capital Employed ranged from a high of 53.99% in Q1 2022 to a low of 194.64% in Q1 2025.
- A 4-year average of 116.93% and a median of 76.03% in 2022 frame the typical range for Return on Capital Employed.
- Annual changes were most pronounced in 2022 — Return on Capital Employed soared 3482 bps — and 2025, when it tumbled 1554 bps.
- Tracing CRDL's Return on Capital Employed over 4 years: stood at 76.03% in 2022, then tumbled by 136 bps to 179.09% in 2024, then fell by 9 bps to 194.64% in 2025, then gained by 10 bps to 175.85% in 2026.
- The last three Return on Capital Employed figures came in at 175.85% (Q1 2026), 194.64% (Q1 2025), and 179.09% (Q1 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.94 Bn | 42.97 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.08 Bn | 39.43 Bn | 2.15 Bn | 6.60% |
| 3 | Zoetis | 31.54 Bn | 29.87 Bn | 1.05 Bn | 17.16% |
| 4 | Takeda Pharmaceutical | 28.60 Bn | 22.80 Bn | 5.10 Bn | 6.07% |
| 5 | United Therapeutics | 22.12 Bn | 19.46 Bn | 683.80 Mn | 22.04% |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | -0.29% |
| 7 | Neurocrine Biosciences | 15.50 Bn | 15.11 Bn | 935.80 Mn | 18.67% |
| 8 | Elanco Animal Health | 11.69 Bn | 11.16 Bn | 798.00 Mn | 5.52% |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.96 Bn | - | - |
| 10 | Cardiol Therapeutics | 213.21 Mn | 194.35 Mn | - | -132.72% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -175.85% |
| Mar 31, 2025 | -194.64% |
| Mar 31, 2024 | -179.09% |
| Dec 31, 2022 | -76.03% |
| Sep 30, 2022 | -74.05% |
| Jun 30, 2022 | -64.84% |
| Mar 31, 2022 | -53.99% |
| Dec 31, 2021 | -80.41% |
| Sep 30, 2021 | -108.87% |